Surmodics, Inc. (NASDAQ:SRDX – Get Rating) Director Jose H. Bedoya sold 4,366 shares of the business’s stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $34.89, for a total value of $152,329.74. Following the transaction, the director now directly owns 24,192 shares in the company, valued at $844,058.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Surmodics Stock Performance
Shares of NASDAQ SRDX traded up $1.21 during mid-day trading on Wednesday, hitting $36.13. 56,070 shares of the stock traded hands, compared to its average volume of 41,679. The stock has a fifty day moving average price of $32.33 and a 200-day moving average price of $34.63. Surmodics, Inc. has a 52 week low of $28.27 and a 52 week high of $50.85. The company has a market cap of $507.27 million, a price-to-earnings ratio of -18.27 and a beta of 0.98.
Analyst Ratings Changes
Separately, StockNews.com began coverage on Surmodics in a research note on Wednesday, October 12th. They set a “hold” rating on the stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Teachers Retirement System of The State of Kentucky bought a new position in shares of Surmodics during the third quarter valued at $87,000. BNP Paribas Arbitrage SNC increased its position in Surmodics by 34.4% in the third quarter. BNP Paribas Arbitrage SNC now owns 4,854 shares of the company’s stock worth $148,000 after buying an additional 1,243 shares in the last quarter. State Street Corp boosted its stake in shares of Surmodics by 1.1% in the third quarter. State Street Corp now owns 508,352 shares of the company’s stock worth $15,454,000 after acquiring an additional 5,296 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Surmodics by 5.3% in the third quarter. Thrivent Financial for Lutherans now owns 14,477 shares of the company’s stock worth $440,000 after acquiring an additional 733 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Surmodics by 1.7% in the third quarter. Vanguard Group Inc. now owns 974,726 shares of the company’s stock worth $29,632,000 after acquiring an additional 15,867 shares during the period. 97.00% of the stock is owned by institutional investors.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).